Xspray-logo-white
  • Home
  • About us
    • Business model
    • Our history – a timeline
    • Board of Directors & Board committees
    • Management
  • Technology
  • Pipeline
  • Media
  • Contact
  • Investors
  • en en
    • sv sv
  • Investors
    • Share information
      • Ownership structure
    • Financial calendar & Events
    • Financial reports
      • ESEF report
    • Prospectus
    • Press releases
    • Corporate governance
      • Corporate Structure
      • General meetings
      • Corporate Governance Reports
      • Nomination committee
      • Board of Directors & Board committees
      • Management
      • Accounting principles
      • Internal control & Risk management
      • Auditor
      • Articles of association
      • Remuneration

Press releases

All press releases Regulatory

Press release 2021-04-08

Xspray Pharma announces update of its improved version of dasatinib

Regulatory press release 2021-04-08

Xspray Pharma announces the results of two bioequivalence studies with adjusted tablet formulation of HyNap-Dasa (ANDA)

Regulatory press release 2021-03-19

Xspray Pharma publishes its annual report for 2020

Press release 2021-03-18

Xspray Pharma aims to submit its improved version of dasatinib for market approval application in second half of 2021

Press release 2021-03-05

Both groups in the two ongoing bioequivalence studies with Xspray Pharma’s product candidate HyNap-Dasa have been dosed

Regulatory press release 2021-02-25

Xspray Pharma publishes Interim report Q4, January – December 2020

Regulatory press release 2021-02-17

Nomination Committee proposes Anders Ekblom as new Chairman of the Board in Xspray Pharma

Regulatory press release 2021-01-29

Number of shares and votes in Xspray Pharma

Regulatory press release 2021-01-26

Warrant holders exercise all warrants within the framework of the incentive program

Regulatory press release 2021-01-22

Xspray Pharmas study with modified formulation of HyNap-Dasa has now started

Show more

IR contact

Kerstin Hasselgren, IRO / Senior Adviser

+46 (0)70 311 16 83

info@xspray.com

Subscribe

  • Submit to our press releases and get an email every time we publish a press release or report on our website.
  • When clicked on Send I agree that my personal information will be saved. Read more
  • This field is for validation purposes and should be left unchanged.
Xspray-logo-white

Xspray Pharma AB Scheeles väg 2 171 65 Solna

+46 (0)8 730 37 00 info@xspraypharma.com

We use cookie to give you the best experience of our site. If you continue to use this website we will assume you agree. Read more about our Privacy policy.I agree